Results 181 to 190 of about 3,743 (224)

Nephroprotection by Antihypertensive Agents

Journal of Cardiovascular Pharmacology, 1994
Arterial hypertension is one of the few factors confirmed to accelerate the development of renal failure. Conversely, several studies have documented that systematic reduction of the blood pressure slows the progression of renal failure. It is postulated that 24-h reduction of the blood pressure should be achieved, best controlled by ambulatory blood ...
openaire   +2 more sources

Wine, sirtuins and nephroprotection: Not only resveratrol

Medical Hypotheses, 2010
Resveratrol (RSV), a red wine component, and red wine itself exert cardio- and nephroprotective effects by modulating the Nitric Oxide system (NO). It has been shown that one of the main actions resulting from NO modulation is sirtuin regulation, especially SIRT-1 regulation.
Mannari C, Bertelli AA, Stiaccini G, GIOVANNINI, LUCA   +3 more
openaire   +4 more sources

Nephroprotection and iodinate contrast medias

Radiología (English Edition)
The incidence of post-contrast acute kidney injury (PC-AKI) is low with the new low- or iso-osmolar non-ionic iodinated contrast agents. The only proven form of prophylaxis for PC-AKI is hydration, preferably intravenous, although oral hydration is equally effective.
C, Sebastià, S, Falip, R, Crespo, E, Guillen, C, Nicolau, E, Poch, L, Oleaga   +6 more
openaire   +2 more sources

Nephroprotection with saxagliptin.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015
The nephroprotective effect of the new anti-diabetic drugs acting on incretin system is suggested by preclinical studies. However, no study evaluating kidney effects of these drugs as primary outcome on the long term has been conducted in patients followed in diabetes centers.
Iazzetta, Nicolangelo, Garofalo, Carlo, Savino, Manuela, Sagliocca, Adelia, Santangelo, Sara, Pacilio, Mario, Liberti, Maria Elena, Camocardi, Andrea, Ambrosca, Camilla, MINUTOLO, Roberto, DE NICOLA, Luca, CONTE, Giuseppe   +11 more
openaire   +2 more sources

[Gliflozins: Proteinuria Control and Nephroprotection].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
In recent years, the prevalence of chronic kidney disease (CKD) has significantly increased, with an estimated 843.6 million individuals affected in 2017 [1]. This rise is closely linked to the growing incidence of risk factors such as diabetes mellitus and obesity.
Barbuto, Simona, Catalano, Veronica, Pira, Marianna, Cianciolo, Giuseppe, Comai, Giorgia, Capelli, Irene, Tondolo, Francesco, Maritati, Federica, La Manna, Gaetano   +8 more
openaire   +2 more sources

Blood Pressure Control and Nephroprotection in Diabetes

The Journal of Clinical Pharmacology, 2004
Achievement of recommended levels of blood pressure as prescribed by guidelines (i.e., systolic blood pressure of < 130 mmHg in people with nephropathy secondary to type 2 diabetes) generally requires three or more different antihypertensive agents that have complementary modes of action.
Kevin, Abbott, Emad, Basta, George L, Bakris   +2 more
openaire   +2 more sources

Nephroprotective Effect of Bosentan in Diabetic Rats

Journal of Cardiovascular Pharmacology, 2003
Previous studies have suggested that endothelins could be involved in the pathogenesis of target organ damage in diabetes. The aim of this study was to evaluate the possible protective effect of Bosentan, an antagonist of endothelin receptor, on the kidney of diabetic rats.
COSENZI, ALESSANDRO, BERNOBICH E, TREVISAN R, MILUTINOVIC N, BORRI A, BELLINI G.   +5 more
openaire   +3 more sources

[New perspectives for bradykinin in nephroprotection].

Medecine sciences : M/S, 2007
Various diseases such as arterial hypertension, diabetes and obesity result in renal diseases which are often irreversible and resistant to currently available therapies. Beside the control of glycemia in diabetic patients, only the blockade of the renin-angiotensin system is effective in reducing the occurrence of glomerulosclerosis and its ...
Buléon, Marie, Mehrenberger, Marion, Pécher, Christiane, Praddaude, Françoise, Couture, Réjean, Tack, Ivan, Girolami, Jean-Pierre   +6 more
openaire   +2 more sources

[Nephroprotection, fact or fiction?].

Presse medicale (Paris, France : 1983), 2011
Clinical studies of the last 15 years have shown the benefit of pharmacological interventions on the progression of chronic kidney disease, confirming the concept of nephroprotection. Pharmacological blockade of the renin angiotensin system remains the cornerstone of the nephroprotective treatment but the benefits and limitations are now better defined.
Thierry, Krummel, Anne-Laure, Faller, Dorothée, Bazin, Thierry, Hannedouche   +3 more
openaire   +1 more source

[New aspects of pharmacological nephroprotection].

Innere Medizin (Heidelberg, Germany), 2022
Current estimates forecast that chronic kidney diseases will be the fifth most common cause of death worldwide by 2040. The prevalence of chronic renal diseases increases with age and, in many countries, affects patients with overweight, diabetes and hypertension.
openaire   +1 more source